By Helena Smolak


GSK posted positive results in a late stage trial for its asthma treatment Nucala in adults with chronic obstructive pulmonary disease.

The British pharma giant said Friday that the trial met its primary endpoint as the antibody showed a reduction in the rate of moderate, severe exacerbations that cause damage to lungs.

Its preliminary safety results are consistent with the known safety profile of the drug. Nucala was first approved in 2015 for severe asthma but is currently not indicated for COPD anywhere in the world, the company said.


Write to Helena Smolak at helena.smolak@wsj.com


(END) Dow Jones Newswires

09-06-24 0242ET